Hepatic steatosis develops after liver transplantation (LT) in 30% of adults, and nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in nontransplanted children. However, posttransplant steatosis has been minimally studied in pediatric LT recipients. We explored the prevalence, persistence, and association with chronic liver damage of hepatic steatosis in these children. In this single-center study of pediatric patients transplanted 1988-2015 (n 5 318), 31% of those with any posttransplant biopsy (n 5 271) had 1 biopsy with steatosis. Median time from transplant to first biopsy with steatosis was 0.8 months (interquartile range [IQR], 0.3-6.5 months) and to last biopsy with steatosis was 5.5 months (IQR, 1.0-24.5 months); 85% of patients with steatosis also had for-cause biopsies without steatosis. All available for-cause biopsies were re-evaluated (n 5 104). Of 9 biopsies that could be interpreted as nonalcoholic steatohepatitis (NASH)/borderline NASH, with steatosis plus inflammation or ballooning, 8 also had features of cholestasis or rejection. Among 70 patients with surveillance biopsies 3.6-20.0 years after transplant, only 1 overweight adolescent had a biopsy with NAFLD (grade 1 steatosis, mild inflammation, no ballooning or fibrosis)-despite a 30% prevalence of overweight/obesity in the cohort and 27% with steatosis on previous for-cause biopsy. Steatosis on preceding for-cause biopsy was not associated with portal (P 5 0.49) or perivenular fibrosis (P 5 0.85) on surveillance biopsy. Hepatic steatosis commonly develops early after transplant in children and adolescents, but it rarely persists. Biopsies that did have steatosis with NASH characteristics were all for-cause, mostly in patients with NAFLD risk factors and/or confounding causes of liver damage. Prospective studies that follow children into adulthood will be needed to evaluate if and when hepatic steatosis presents a longterm risk for pediatric LT recipients.
for liver diseases that do not recur after transplant. For children, threats to longterm graft health include rejection, vascular and biliary issues, and chronic liver diseases like viral hepatitis or nonalcoholic fatty liver disease (NAFLD).
NAFLD is the most common cause of chronic liver disease in US children. (2) Obesity, insulin resistance, and metabolic syndrome are strongly associated with NAFLD. We have recently reported that longterm survivors after pediatric LT have a similar high prevalence of obesity-approximately 30%-and metabolic syndrome-approximately 15%-as do nontransplanted peers. (3) In adults who undergo LT, at least 30% develop significant steatosis after transplant, with risk increased by posttransplant obesity and metabolic syndrome and by pretransplant steatotic disease. (4) Fibrosis frequently develops in adults with posttransplant NAFLD, and it can progress rapidly. (5) Posttransplant steatosis has not been well studied in pediatric LT recipients. (6, 7) The possibility of steatosisAbbreviations: ACR, acute cellular rejection; AGA, American Gastroenterological Association; ALF, acute liver failure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AZA, azathioprine; BMI, body mass index; CRN, Clinical Research Network; CSA, cyclosporine; DDLT, deceased donor liver transplantation; FIC1, familial intrahepatic cholestasis 1; FXR, farnesoid X receptor; GGT, gamma-glutamyl transpeptidase; HPF, high-power field; IQR, interquartile range; LRLT, living related liver transplantation; LT, liver transplantation; MMF, mycophenolate mofetil; NA, not applicable; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; PFIC, progressive familial intrahepatic cholestasis; Pred, prednisone; TAC, tacrolimus; TPN, total parenteral nutrition; UCSF, University of California, San Francisco.
associated chronic liver damage has not been an analytical focus in descriptions of longterm liver graft histology. (8, 9) Steatosis prevalence has been reported in 10%-43% of pediatric LT surveillance biopsies in cross-sectional studies. However, none of these studies evaluates longitudinally whether steatosis persists, should be classified as NAFLD or related to other conditions, or contributes to longterm graft damage. (10) (11) (12) (13) In this analysis, we explored the prevalence and persistence of steatosis after pediatric LT, and investigated whether steatosis might be associated with chronic graft damage.
Patients and Methods
We analyzed single-center data from (1) a retrospective review of records on pediatric LT recipients and (2) a cross-sectional study on a subset of the cohort conducted from September 2012 to August 2016. All patients at our center receive induction with corticosteroids after transplant and are weaned off as tolerated within 2-4 months. All remain on a longterm calcineurin inhibitor (tacrolimus [TAC] or cyclosporine [CSA] ) and receive mycophenolate mofetil (MMF) for 0.8-2.0 years after transplant. This study was approved by the University of California, San Francisco (UCSF) Committee on Human Research (CHR 10-01363, 12-10290, 14-13939) prior to data extraction; participants in the crosssectional study gave consent/assent prior to participation and consented for review of medical records.
FIG. 1.
Retrospective analysis of hepatic steatosis in posttransplant liver biopsies of pediatric LT recipients, detailing samples available for evaluation and histologic outcomes for patients in the cohort. Surveillance biopsies are shaded gray; all other biopsies described were for-cause. Characteristics of patients with biopsies that met criteria for NASH are detailed in Table 1 . *Eleven biopsies were not available for review, primarily because they had been returned to a referring center. An additional 24 were not assessable due to faded stains; 22 of 24 were performed before 1996.
HEPATIC STEATOSIS IN FOR-CAUSE BIOPSIES-RETROSPECTIVE ANALYSIS
Our initial cohort for retrospective analysis included all patients transplanted at UCSF between January 1988 and June 2015, < 21 years of age at transplant. Original pathology reports on liver biopsies for all 318 patients were reviewed to identify patients with steatosis in any posttransplant biopsy (Fig. 1) . "For-cause" biopsies were performed for clinical suspicion of rejection, hepatitis, or other pathology. Eleven biopsies were not available for review, primarily because they had been returned to a referring center. An additional 24 were not assessable due to faded stains; 22 of 24 were performed before 1996.
Available for-cause biopsies with steatosis noted on the original pathology report were reread by a single liver pathologist (R.R.). Because steatosis and its significance has been minimally studied after pediatric LT and because many of these biopsies occurred before NAFLD/nonalcoholic steatohepatitis (NASH) were well-characterized entities in children, the research read was a blinded reinterpretation of whether NAFLD or NASH-like pathology was present. To standardize the interpretation and consider whether previously undetected NAFLD/NASH might be present, we used the NASH Clinical Research Network (CRN) histologic scoring system to evaluate steatosis severity and for other NASH features (14) : steatosis (grade 0, < 5% macrovesicular; grade 1, 5%-33%; grade 2, 34%-66%; or grade 3, > 66%), portal inflammation (none, mild, more than mild), lobular inflammation (none, < 2 foci/high-power field [HPF], 2-4 foci/HPF, or > 4 foci/HPF), ballooning degeneration (none, few, or many), and fibrosis (stage 0; stage 1a, mild perisinusoidal; stage 1b, moderate perisinusoidal; stage 1c, portal/periportal fibrosis only; stage 2, zone 3 and periportal; stage 3, bridging fibrosis; and stage 4, cirrhosis). In addition, biopsies were classified as "NASH" or "borderline NASH" based on the pathologist's overall assessment of the biopsy and as "not NASH" if diagnostic features of NASH were absent. (14) Data on demographics, transplant, outcomes, anthropometrics, and medications were collected from the electronic medical record. Explant data were missing for most patients (72 of 84 with steatosis, 158 of 187 with no steatosis reported).
HEPATIC STEATOSIS IN SURVEILLANCE BIOPSIES-RETROSPECTIVE ANALYSIS
In August 2013, our center instituted standard-of-care surveillance liver biopsies starting 3-5 years after transplant. (9, 13) Additional patients underwent surveillance liver biopsies in the National Institutes of Health- National Institute of Diabetes and Digestive and Kidney Diseases immunosuppression withdrawal trials (NCT01638559; NCT00320606). All surveillance biopsies were interpreted by a single pathologist (K.J.), per our center's standardized protocol; steatosis grading and NASH diagnosis was again based on the NASH CRN system. (14) These reads were extracted retrospectively from the medical record.
HEPATIC STEATOSIS SCREENING-CROSS-SECTIONAL STUDY
We enrolled 83 pediatric LT recipients, all included in the retrospective analysis, in a cross-sectional study of posttransplant metabolic syndrome and its consequences-including NAFLD. Participants were < 21 years old at transplant, 8-30 years old at study visit, 1 year from last LT, and on a stable immunosuppressive regimen. All had anthropometrics and 2-hour glucose tolerance testing done according to National Health and Nutrition Examination Survey 2011 protocols (http://wwwn.cdc.gov/nchs/nhanes/ContinuousNhanes/ manuals.aspx?BeginYear=2011).
To assess for hepatic steatosis, patients underwent liver ultrasound during the study visit using a Logiq E9 ultrasound machine (General Electric, Milwaukee, WI) with a 6 MHz curved transducer. Study ultrasounds were interpreted by a single pediatric radiologist (A.P.) and overread by a second radiologist (V.A.F.); any discrepancies in interpretation were resolved by group consensus of the 2 radiologists. All recorded images were evaluated for (1) hepatic parenchymal echogenicity; (2) relative echogenicity of the liver to right kidney; (3) deep attenuation of the sound beam; and (4) relative echogenicity of the portal triads and walls of the hepatic vessels compared with background liver. (15, 16) Overall assessment of hepatic steatosis was based on these characteristics.
CLASSIFICATION OF ANTHROPOMETRICS-RETROSPECTIVE AND CROSS-SECTIONAL DATA
For patients younger than 18 years at measurement, body mass index (BMI) percentile for age and sex was calculated based on 2000 Centers for Disease Control growth chart data. (17) BMI percentile 85th-94th percentile for age and sex was overweight, and 95th percentile was obese. In patients 18 years, overweight was a BMI of 25-29.9 kg/m 2 , and obese was a BMI of 30 kg/m 2 .
STATISTICAL ANALYSIS
Analysis focused on descriptive statistics. Median and interquartile range (IQR) was used to describe distribution for nonnormally distributed variables, mean and standard deviation for those with normal distributions. All data were collected in a REDCap database and analyzed using Stata 14 (Stata Corp., College Station, TX).
Results

EVOLUTION AND RESOLUTION OF HEPATIC STEATOSIS IN FOR-CAUSE BIOPSIES
Our retrospective cohort included 318 pediatric LT recipients. At least 1 for-cause biopsy was done in 85%, and 64% had > 1 (range, 2-36; Fig. 1 ). A total of 84 children had at least 1 for-cause biopsy with steatosis noted on the original pathology report (Table 1) . In these 84, 22% of all for-cause biopsies (n 5 624) were reported to have steatosis. Eight patients had 15 biopsies each. The remaining 76 patients had a median 4.5 biopsies each (IQR, 3.0-8.0). No patients underwent transplantation for NASH. Figure 2 demonstrates the timing of biopsies with steatosis in these 84 patients; most of the biopsies with steatosis were done within 2 months after transplant. Median time between transplant and first for-cause biopsy with steatosis was 0.8 months (IQR, 0.3-6.5 months). Median time to last for-cause biopsy with steatosis was 5.5 months after transplant (IQR, 1.0-24.5 months). Of the patients with steatotic biopsies, 85% also had for-cause biopsies without steatosis.
Of the 50 patients with steatosis in only 1 biopsy, median time between transplant and steatotic biopsy was 0.8 months (IQR, 0.3-13.3 months). Among those with > 1 for-cause biopsy (n 5 46), 87% had steatosis resolution in subsequent liver biopsies. Only 1 of these 50 biopsies was classified as NASH on the original pathology read; it was in an overweight patient 9.8 years after transplant, with grade 2 macrovesicular steatosis and inflammation, no significant fibrosis, and no other posttransplant biopsies in our system (Table 1) .
Of the 23 patients with steatosis in 2 for-cause biopsies, 69% had resolution documented by subsequent biopsies. The median time to first biopsy with steatosis was 0.2 months after transplant (IQR, 0.5-4.9 months), and the time to second biopsy was 2.3 months after transplant (IQR, 0.7-15.2 months). Three of these 23 patients had biopsies with steatosis and NASH features. Two of the 3 were within 1 month after transplant; steatosis resolved in both patients. The third had a biopsy with steatosis grade 1 and NASH features at 2 months after she was retransplanted for idiopathic cirrhosis. At 14 months after her second transplant, the patient had another biopsy with steatosis grade 3 and similar inflammation, but no ballooning (Table 1) .
Of the 7 patients with steatosis in 3 for-cause biopsies, median time to first steatotic biopsy was 1.1 month after transplant (IQR, 0.3-7.7 months) and time to third was 11.7 months (IQR, 2.9-64.8 months); 71% had resolution in subsequent biopsies without a known recurrence. One progressed to NASH by 5.5 years after transplant. A second had subsequent biopsies that showed features of acute and chronic rejection with persistent steatosis of varying severity (Table 1) .
Four patients had steatosis in 4 for-cause biopsies. All 4 had the first steatotic biopsy within 1.2 months after transplant. Two had the first steatotic biopsy within 1 month after transplant while recovering from preservation injury, and both had improved but not resolved steatosis at last biopsy (6 and 9 months after transplant, respectively). A third, transplanted at 1 year of age for biliary atresia, had grade 2 steatosis while on corticosteroids that resolved. The steatosis then recurred as persistent grade 1 steatosis through 2 years after transplant. The fourth had progressive familial intrahepatic cholestasis (PFIC) type 1, as detailed below. None had features of NASH-like ballooning or characteristic inflammation.
STEATOSIS IN PATIENTS WITH PFIC
Six of the patients underwent transplantation for confirmed PFIC type 1 or low-gamma-glutamyl transpeptidase (GGT) PFIC. PFIC type 1 has been linked to hepatic steatosis in previous case series. (18) Three of the 6 PFIC patients had posttransplant steatosis. One 14-year-old had grade 1 steatosis on biopsy 1 month after living related transplant, and then normal aspartate aminotransferase (AST)/alanine aminotransferase (ALT) with no later biopsies. A second developed grade 2 macrovesicular steatosis without inflammation or fibrosis 2 years after living related transplant. A third had 4 forcause biopsies and had grade 1-3 macrovesicular steatosis over 11 years of follow-up, with mild portal inflammation, and eventually stage 2 pericellular fibrosis. This patient had several episodes of acute cellular rejection (ACR) treated with corticosteroid pulses, and he was the only PFIC patient to suffer from chronic diarrhea and malnutrition. The 3 other PFIC patients had no available biopsies >16 months after transplant.
CHARACTERISTICS OF FOR-CAUSE BIOPSIES WITH STEATOSIS
A single liver pathologist re-evaluated all available forcause biopsies with steatosis (n 5 104, on 68 patients) to evaluate for other characteristics of NASH. The pathologist was blinded to clinical data. Of biopsies adequate for review (Fig. 1) , 20% had grade 3 steatosis; 23% had grade 2; 34% had grade 1; and the remaining 23% had grade 0 (<5%). Only 1 biopsy had exclusively microvesicular fat. This was a 1-month posttransplant biopsy in a child who received a whole deceased donor liver for maple syrup urine disease. At 3 months, her for-cause biopsy had grade 2 macrovesicular fat. Biopsies at 6 months and 1 year showed no steatosis.
Of the reviewed biopsies with steatosis, 90% did not have any features suggestive of NASH. The 7 patients who did have a biopsy that met criteria for NASH/ borderline NASH on pathology re-evaluation are detailed in Table 1 . Of 4 biopsies that met criteria for NASH, 2 had been diagnosed with NASH on the original pathology read. All 4 had ballooned hepatocytes and at least grade 2 steatosis. Five biopsies had findings that could be interpreted as borderline NASH. Three of these 5 had steatosis with hepatocellular ballooning; all 5 had features of other types of liver damage (Table 1 ). All 7 patients were Latino or Caucasian, and 80% of those with data available were overweight/obese.
Four of these 7 patients had steatosis resolution on subsequent biopsies ( Fig. 1 ; Table 1 ). Two of 3 who were more than 3 years after transplant also had features of chronic rejection and chronic corticosteroid exposure. The last patient had 1 biopsy with NASH as an obese adult; she died from unrelated causes. One of the 7 required retransplant because of hepatitis B recurrence. Fifteen of the biopsies with steatosis also met criteria for acute rejection on the research read.
HEPATIC STEATOSIS IN SURVEILLANCE BIOPSIES
Surveillance biopsies were available on 70 patients (Table 2) . Of these, 85% were on TAC and 15% were on CSA. One patient was on prednisone (Pred) of 1 mg daily. Patients had liver enzymes in the normal range, and almost 1/3 were overweight/obese (Table  2) . No PFIC patients had a surveillance biopsy.
Only 1 surveillance biopsy had significant steatosis (>5%); it was grade 1. This was a female patient transplanted for biliary atresia with a living donor. The biopsy was 8 years after transplant. The biopsy had mild portal and lobular inflammation but no ballooning or fibrosis. Ultrasound on the same day was read as no steatosis. At biopsy, her BMI was 97th percentile, and she was on TAC with AST and ALT < 35 IU/L. She had an additional surveillance biopsy 13 years after transplant, with no steatosis and no fibrosis. Her BMI remained 97th percentile, and she was off immunosuppression. Her only previous for-cause biopsy was 6 days after transplant, with no steatosis.
Four additional patients had surveillance biopsies with very mild steatosis, in <5% of hepatocytes. Two had previous for-cause biopsies with steatosis, also <5%. Of interest, both had glucose intolerance (oral glucose tolerance test with 2-hour blood glucose > 140 mg/dL), but neither had diabetes or previous insulin requirement. One was an obese Latino adolescent male with insulin resistance. The second was a normal weight Caucasian adolescent female transplanted for a urea cycle disorder. The other 2 with < 5% steatosis on surveillance biopsy had previous forcause biopsies without steatosis. Again, 1 was an obese Latino adolescent male with insulin resistance. The last was a normal weight Caucasian adolescent female. All 4 had minimal lobular inflammation with no portal or interface inflammation, no portal fibrosis, and no hepatocellular ballooning. One had mild perivenular fibrosis.
Of the 70 patients with surveillance biopsies, 62 had previous for-cause biopsies and 27% had steatosis on at least 1 for-cause biopsy. There was no correlation between portal fibrosis on surveillance biopsy and steatosis on preceding for-cause biopsies (P 5 0.49). Of the patients with previous steatosis, 71% had no portal fibrosis, 6% had stage 1, and 24% had stage 2-3. Among patients without previous steatosis, 73% had no portal fibrosis, 13% had stage 1, and 13% had stage 2-3. Perivenular fibrosis on surveillance biopsy also had no association with steatosis on previous for-cause biopsies (P 5 0.85, chi-square test). Perivenular fibrosis was moderate/severe in 18% of those with previous steatosis and 13% without previous steatosis, and it was mild in 35% and 42%, respectively.
ULTRASOUND SCREENING FOR HEPATIC STEATOSIS
Fifty-six patients with surveillance biopsies also participated in a cross-sectional study of posttransplant metabolic syndrome, (3) during which they underwent abdominal sonography for NAFLD screening. In addition, 27 patients without surveillance biopsies participated in the research screening.
One patient was judged to have moderate hepatic steatosis on screening ultrasound (1.2%). She had a for-cause liver biopsy confirming NASH 3 months prior to study visit and no surveillance biopsies. She was the only patient with a biopsy read as NASH (Table 1) in the cross-sectional study. All 4 patients with steatosis < 5% on surveillance biopsy had ultrasounds read as no steatosis.
Eleven (12%) patients had ultrasounds reported as mild hepatic steatosis. Of these, 4 had surveillance liver biopsies within 3 months. None had steatosis; however, all 4 had mild portal inflammation and 3 had minimal lobular inflammation. Two had mild perivenular fibrosis, and 1 had moderate/severe perivenular and portal fibrosis. Two of the 11 had previous forcause biopsies with no steatosis (1.5 years and 7.5 years prior to study visit) but no biopsies within 1 year of study visit. The other 6 patients had no posttransplant liver biopsies. The 11 patients with mild hepatic steatosis on research ultrasound were more likely to be overweight or obese (55%) than the study patients without hepatic steatosis (22%; P 5 0.02), but there were no differences in ALT (median, 38 versus 29 IU/ L, respectively; IQR, 21-56 versus 21-46 IU/L, respectively; P 5 0.85). Two PFIC patients participated in the cross-sectional study. Both had ultrasounds read as no steatosis.
Discussion
Hepatic steatosis was common within the first months after transplant but not in the long term in our cohort of pediatric LT recipients. The majority of steatosis detected was mild, seen in conjunction with other forms of liver damage, and subsequently resolved. A small minority of patients had biopsies that met criteria for NASH; all had elevated serum transaminases leading to for-cause biopsies.
This analysis follows a sizeable cohort through longterm follow-up, providing novel, longitudinal insight into hepatic steatosis prevalence and persistence in this population. Given the retrospective nature of most of our data collection and the lack of surveillance biopsies in all patients, this is not a definitive account of steatosis incidence or natural history after pediatric LT. Most for-cause biopsies with steatosis were within 1-3 months after transplant, when patients are still on corticosteroids and conditions like preservation injury or vascular complications may still be manifest. (19) In the steatotic biopsies that met criteria for NASH on blinded review, it is key to note that features of rejection-acute and chronic-were common. It is possible that a clinically reviewing pathologist would have labeled the steatosis as related to another diagnosis.
However, given the relatively high prevalence of steatosis early after transplant and the high prevalence of obesity in our cohort, the lack of persistent steatosis and NASH was striking. In nontransplanted patients, NAFLD is seen in 30% of overweight/obese children (2) and in 60%-95% of those with metabolic syndrome. (20) In our surveillance biopsy cohort, we identified steatosis in only 5% of overweight/obese patients and NASH in none. Only 1.8% of biopsied patients had steatosis with NASH characteristics that persisted >1 year after transplant. Only 10% of our for-cause biopsies with steatosis, totaling <1% of all for-cause biopsies performed in our cohort, met criteria for NASH.
All biopsies that had steatosis and met criteria for NASH were for-cause, performed on patients with elevated transaminases. All 7 patients were Latino or Caucasian, and 80% of those with data available were overweight/obese. However, most also had features of other liver injury types, including rejection and cholestasis. In the surveillance biopsies with any hepatic steatosis, characteristics associated with NAFLD were also common: all were Latino or Caucasian; 4 were adolescents; 3 of 5 were overweight/obese; and 3 were with abnormal glucose tolerance. The 1 other study that examined posttransplant NAFLD and metabolic syndrome in children also suggested a connection. Of their 7 patients with posttransplant metabolic syndrome, 6 had steatosis. (10) Thus, suspicion for NASH or NAFLD should be highest in our patients with traditional NAFLD risk factors.
In our cross-sectional study, ultrasound was not reliable as a screen for mild hepatic steatosis. Although ultrasound is known to have limited sensitivity for steatosis, our data suggest that it may also have limited specificity in the LT population-as 4 patients with ultrasound suggestive of steatosis had none on biopsy. We identified only 1 patient with moderate steatosis. It is possible that obesity in some patients contributed to the interpretation of ultrasound echogenicity as mild steatosis because obesity prevalence was higher in these patients. Even if the patients with mild steatosis on ultrasound and without confirmatory biopsy did have steatosis, this would amount to a prevalence of 6%-10%-again despite a 27% prevalence of overweight/ obesity.
The 4 previous pediatric LT surveillance biopsy studies that describe steatosis all report higher prevalence than in our cohort. None followed steatosis evolution over time. Kosola et al. reported the highest prevalence: 43% in surveillance biopsies (n 5 56) done 3-22 years after transplant. (10) Sixty-five percent of their patients were on low-dose corticosteroids, but other clinical characteristics were similar.
Notably, the histologic description of steatosis in the cohort from Kosola et al. was quite different. Of their biopsies, 80% were read as microvesicular steatosis, and 20% were read as mixed micro/macrovesicular steatosis. Of those with macrovesicular steatosis, all had grade 1 with no other NASH features. (21) Neither inflammation nor fibrosis was associated with steatosis. (10, 21) Thus, they similarly describe a very low prevalence of biopsies meeting NASH criteria, and no clear evidence of longterm impact on the graft.
Venturi et al. identified steatosis in 27% of surveillance biopsies (n 5 71), done at 0.5 and 7.0 years after transplant. Most of their patients were also on corticosteroids. Their data suggested, as did ours, that significant steatosis may be accompanied by ALT elevation. (11) In a German cohort of 60 children, 17% had grade 1 steatosis on surveillance biopsies 1-17 years after transplant. Most were on low-dose corticosteroids. (13) Finally, in a Japanese study of 59 surveillance biopsies 0.2-15.0 years after transplant, 10% had mild steatosis. (12) In adults after LT, NASH is a risk factor for progression to bridging fibrosis and cirrhosis. We did not find a correlation between steatosis in for-cause biopsies and fibrosis in later surveillance biopsies. The Finnish and Japanese studies also identified no association between steatosis and fibrosis in their crosssectional biopsies. (12, 21) Prospective evaluation with repeated surveillance biopsies will be required to definitively judge the role of hepatic steatosis in longterm graft health for children.
We also examined whether steatosis was associated with specific transplant indications. Our previous systematic review identified only 9 patient reports/series, reporting on 19 patients, focused on posttransplant steatosis in children. All of these cases cited specific risk factors: posttransplant thrombosis or preservation injury, pretransplant NASH, panhypopituitarism, or PFIC. (7) We did see steatosis in 50% of our patients transplanted for low-GGT PFIC, which has been reported previously. (18, 22) Interestingly, impaired familial intrahepatic cholestasis 1 (FIC1) function, as seen in PFIC type 1, is thought to down-regulate the farnesoid X receptor (FXR). (23) FXR agonists have shown promise for treatment of NASH in adults.
Important questions remain unanswered by this analysis. Although we suspect that factors like preservation injury, posttransplant corticosteroids, and nutritional supplementation contributed to early steatosis, we could not define the exact contribution of each in this retrospective study. Our center does not routinely biopsy the graft immediately preceding transplant or at reperfusion, so we could not report on donor-derived steatosis. Further delineation of donor versus host risk LIVER TRANSPLANTATION, Vol. 23, No. 7, 2017 PERITO ET AL.
factors is an important topic for future research, given how common NAFLD is in the general population. Follow-up of longterm histology in livers split between adults and children would be one fascinating research strategy.
The major limitations of this study are the reliance on retrospective, for-cause biopsies and the lack of surveillance biopsies in all patients. It is possible that these limitations caused us to underestimate steatosis and NASH prevalence. Not all patients underwent surveillance biopsy, so we cannot definitively rule out steatosis or NASH with normal liver enzymes. However, given our very low prevalence of steatosis also on ultrasound, it seems unlikely that we missed many cases of severe steatosis. Chronic elevation of serum AST or ALT, as seen in active NASH, would trigger a for-cause liver biopsy. We thus suspect that we did not miss a substantial number of NASH cases.
Further research is needed on risk factors for and outcomes associated with persistent hepatic steatosis and NASH in pediatric LT recipients. As knowledge from longterm monitoring and surveillance biopsies builds, we will gain more insight into the clinical importance of these conditions in pediatric patients.
